Cover Story Current Issue

Despite intensive drug development efforts and public health initiatives, obesity is increasing in incidence and predicted to affect over 50% of all adults worldwide by 2035. Being chronically overweight increases the risk of serious disease co-morbidities that, in turn, increase mortality and healthcare costs. Behavioral approaches to combat obesity, such as diet and exercise, rarely produce lasting weight loss commonly due to compensatory hyperphagia and hypometabolism. These limitations have stimulated interest in pharmacotherapies that target gut-derived peptide hormones involved in the regulation of energy homeostasis, such as PYY, GIP, CCK, and GLP-1. These peptides are secreted by different enteroendocrine cells distributed throughout the intestine in response to food intake, subsequently enhancing satiation signaling and ultimately promotes meal termination. However, a major challenge of FDA-approved and experimental weight-loss medications that target GI-derived satiation signals is the frequent occurrence of nausea and vomiting.

Full text

 

Current Issue

Subtyping of type 2 diabetes from a large Middle Eastern biobank: Implications for precision medicine

Nayra M. Al-Thani, Shaza B. Zaghlool, Salman M. Toor, Abdul Badi Abou-Samra, ... Omar M.E. Albagha

Subtyping of type 2 diabetes from a large Middle Eastern biobank: Implications for precision medicine

Type 2 diabetes (T2D) can be classified into Severe Insulin-Deficient Diabetes (SIDD), Severe Insulin-Resistant Diabetes (SIRD), Mild Obesity-related Diabetes (MOD), and Mild Age-related Diabetes (MARD). This classification can help in predicting disease complications and determining the best treatment for individuals. However, the applicability of this classification to non-European populations and sensitivity to confounding factors remain unclear. We applied k-means clustering to a large Middle Eastern biobank cohort (Qatar Biobank; QBB, comprising 13,808 individuals; 2,687 with T2D). We evaluated the efficacy of the European cluster coordinates and analyzed the impact of using actual age on clustering outcomes. We examined sex differences, analyzed insulin treatment frequency, investigated the clustering of monogenic diabetes (MD) focusing on maturity-onset diabetes of the young (MODY), and evaluated the prevalence of chronic kidney disease (CKD) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) among T2D subtypes. We identified the four T2D subtypes within a large Arab cohort. Data-derived centers outperformed European coordinates in classifying T2D. The use of actual age, as opposed to age of diagnosis, impacted MOD and MARD classification. Obesity prevalence was significantly higher in females but it did not translate to worse disease severity, as indicated by comparable levels of HbA1C and HOMA2-IR. Insulin was predominantly prescribed to individuals in SIDD and SIRD. SIRD displayed the highest risk of CKD and MASLD, followed by MOD and SIDD compared to MARD. Interestingly, most MODY individuals were clustered within MARD, further highlighting the need for precise classification and tailored interventions. The observed sex differences underscore the importance of tailoring treatment plans for females compared to males. Individuals who are at a higher risk of CKD and MASLD may require closer monitoring and physician oversight. Additionally, in populations without access to genetic testing, likely MODY individuals can be identified within the MARD cluster. Our findings strongly support the need for a transition to more personalized, data-driven treatment approaches to minimize diabetes-related complications and improve disease outcomes.

Articles in Press

Subtyping of type 2 diabetes from a large Middle Eastern biobank: Implications for precision medicine

Nayra M. Al-Thani, Shaza B. Zaghlool, Salman M. Toor, Abdul Badi Abou-Samra, ... Omar M.E. Albagha

Subtyping of type 2 diabetes from a large Middle Eastern biobank: Implications for precision medicine

Type 2 diabetes (T2D) can be classified into Severe Insulin-Deficient Diabetes (SIDD), Severe Insulin-Resistant Diabetes (SIRD), Mild Obesity-related Diabetes (MOD), and Mild Age-related Diabetes (MARD). This classification can help in predicting disease complications and determining the best treatment for individuals. However, the applicability of this classification to non-European populations and sensitivity to confounding factors remain unclear. We applied k-means clustering to a large Middle Eastern biobank cohort (Qatar Biobank; QBB, comprising 13,808 individuals; 2,687 with T2D). We evaluated the efficacy of the European cluster coordinates and analyzed the impact of using actual age on clustering outcomes. We examined sex differences, analyzed insulin treatment frequency, investigated the clustering of monogenic diabetes (MD) focusing on maturity-onset diabetes of the young (MODY), and evaluated the prevalence of chronic kidney disease (CKD) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) among T2D subtypes. We identified the four T2D subtypes within a large Arab cohort. Data-derived centers outperformed European coordinates in classifying T2D. The use of actual age, as opposed to age of diagnosis, impacted MOD and MARD classification. Obesity prevalence was significantly higher in females but it did not translate to worse disease severity, as indicated by comparable levels of HbA1C and HOMA2-IR. Insulin was predominantly prescribed to individuals in SIDD and SIRD. SIRD displayed the highest risk of CKD and MASLD, followed by MOD and SIDD compared to MARD. Interestingly, most MODY individuals were clustered within MARD, further highlighting the need for precise classification and tailored interventions. The observed sex differences underscore the importance of tailoring treatment plans for females compared to males. Individuals who are at a higher risk of CKD and MASLD may require closer monitoring and physician oversight. Additionally, in populations without access to genetic testing, likely MODY individuals can be identified within the MARD cluster. Our findings strongly support the need for a transition to more personalized, data-driven treatment approaches to minimize diabetes-related complications and improve disease outcomes.

SAVE THE DATE!

13th
Helmholtz Diabetes Conference 
Munich, 21-23. Sep 2026                                                                                                                             

2024 impact factor: 6.6

You are what you eat

Here is a video of Vimeo. When the iframes is activated, a connection to Vimeo is established and, if necessary, cookies from Vimeo are also used. For further information on cookies policy click here.

Auf Werbeinhalte, die vor, während oder nach Videos von WEBSITE-URL eingeblendet werden, hat WEBSITE-URL keinen Einfluss. Wir übernehmen keine Gewähr für diese Inhalte. Weitere Informationen finden Sie hier.